Hepion Pharmaceuticals Inc (HEPA)

NASDAQ
0.691
-0.012(-1.71%)
After Hours
0.713
+0.021(+3.082%)
- Real-time Data
  • Volume:
    115,454
  • Day's Range:
    0.681 - 0.707
  • 52 wk Range:
    0.490 - 1.850
Earnings results expected in 12 days

HEPA Overview

Prev. Close
0.703
Day's Range
0.681-0.707
Revenue
-
Open
0.69
52 wk Range
0.49-1.85
EPS
-0.601
Volume
115,454
Market Cap
52.69M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
166,495
P/E Ratio
-1.17
Beta
1.39
1-Year Change
-52.98%
Shares Outstanding
76,229,617
Next Earnings Date
Aug 31, 2022
What is your sentiment on Hepion Pharmaceuticals?
or
Market is currently closed. Voting is open during market hours.

Hepion Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Hepion Pharmaceuticals Inc Analysis

Hepion Pharmaceuticals Inc Company Profile

Hepion Pharmaceuticals Inc Company Profile

Employees
20

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, Rencofilstat (formerly CRV431), is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. Rencofilstat is a pan cyclophilininhibitor that targets multiple pathologic pathways involved in the progression of liver disease. It provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellSellStrong Sell
Technical IndicatorsSellSellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell
  • 1.05 is quite delicious :)
    0
    • Why is it showing 0.627? This stock closed at 1.59.
      0
      • Another offering up for vote, bad news
        0
        • Hepion was supposed to release treatment results in February and they never did. I suggest to newcomers...don't invest here. They lost credibility by missing deadlines. Moreover, investors bought at 2.00 and they are losing. Just wait for news to come in its website then you are welcome to come. Daytraders are likely winning because the oscillations here are so rewarding if you focus on profiting from the continous downtrend, don't wait for miracles in the long term until you have solid news. Cheers
          0
          • Be ready to buy at 1 USD :D....enjoy the ride
            7
            • Poor private company that bought shares at 2.00. They must be regreting. Now I buy at a lower price :). 1.7 is quite delicious. even if it drops to 1 due to the global crisis...is an amazing value for the long run...
              7
              • This comment didn't age well..
                0
            • I like the stock!
              0
              • Why -20% in Pre Market?
                0
                • Buying oppurtinity now, after the offering
                  0
                  • Wow... Big Red... Cinnamon.
                    0